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Abstract
The purpose of the present study was to investigate the expression
(mRNA) of CD40 ligand (CD40L), interferon-g (IFN-g) and Fas
ligand (FasL) genes in human cardiac allografts in relation to the
occurrence of acute cardiac allograft rejection as well as its possible
value in predicting acute rejection. The mRNA levels were determined
by a semiquantitative reverse transcriptase-polymerase chain reaction
method in 39 samples of endomyocardial biopsies obtained from 10
adult cardiac transplant recipients within the first six months after
transplantation. Biopsies with ongoing acute rejection showed signifi-
cantly higher CD40L, IFN-g and FasL mRNA expression than biop-
sies without rejection. The median values of mRNA expression in
biopsies with and without rejection were 0.116 and zero for CD40L
(P<0.003), 0.080 and zero for IFN-g (P<0.0009), and 0.156 and zero
for FasL (P<0.002), respectively. In addition, the levels of IFN-g
mRNA were significantly increased 7 to 15 days before the appear-
ance of histological evidence of rejection (median of 0.086 in pre-
rejection biopsies), i.e., they presented a predictive value. This study
provides further evidence of heightened expression of immune activa-
tion genes during rejection and shows that some of these markers may
present predictive value for the occurrence of acute rejection.
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Cardiac transplantation is an effective
therapy for end-stage heart disease, but the
occurrence of rejection is a major hazard
following transplantation. Acute rejection
occurs in more than 50% of heart transplant
recipients, is the leading cause of death in the
first year and accounts for approximately
20% of all deaths following heart transplan-
tation (1,2). The gold standard for the di-
agnosis of rejection is the histological evalu-
ation of endomyocardial biopsies and the
most commonly used grading scale for the
diagnosis and staging of rejection is that of
the International Society for Heart and Lung
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Transplantation (ISHLT) (3). Nonetheless,
the histological evaluation of endomyocar-
dial biopsies may present problems of sensi-
tivity and does not always allow discrimina-
tion between mild episodes of rejection which
might be self-limiting from those that may
progress (4,5). Therefore, much effort is be-
ing devoted to other procedures that could
be of additive value to histological grading
and/or that could indicate the onset of a
rejection process before the appearance of
histological alterations. In this setting, im-
munologic markers have been explored both
in biopsies and in peripheral blood. Although
interesting results have been reported, the
perfect marker(s) remain to be established
(2,6-16).
In a previous study using a qualitative
reverse transcriptase-polymerase chain re-
action (RT-PCR) assay, we have shown a
higher rate of detection of mRNA for CD40
ligand (CD40L), interferon-g (IFN-g), IL-8,
granzyme B and Fas ligand (FasL) in endo-
myocardial biopsies with histological fea-
tures of rejection, as well as an increased
frequency of detection of IFN-g and IL-8
mRNA in biopsies that did not show histo-
logical alterations but were preceded or fol-
lowed by rejection within an interval of 7 to
15 days (17,18). These results, however,
could not be accepted as definitive, since the
qualitative RT-PCR assay has the drawback
of not taking into consideration the amount
of total mRNA present in the sample.
In order to further investigate the rela-
tionship between acute cardiac allograft re-
jection and the expression of mRNA of im-
mune activation molecules, we have used a
semiquantitative RT-PCR assay to determine
the level of activation of the CD40L, IFN-g
and FasL genes in the same biopsy samples
as used in the above mentioned study. The
semiquantitative RT-PCR assay is superior
to the qualitative assay since the level of
transcription of the gene under study is nor-
malized by the expression of a gene whose
transcription level is constant (19).
The results herein reported refer to data
obtained for 39 endomyocardial biopsy
samples collected during the first six months
after transplantation from 10 adult cardiac
allograft recipients. The protocol was ap-
proved by the Ethics Committee of the Fed-
eral University of Sªo Paulo and informed
consent was obtained from all subjects un-
der study. All patients were maintained on
standard triple immunosuppression therapy.
Treatment for rejection consisted of pulse
therapy with methylprednisolone (1 g daily
for 3 days) and/or augmentation of the oral
doses of prednisone and cyclosporine. Patho-
logic assessment was performed by two pa-
thologists who were unaware of the mRNA
study results. Rejection was graded accord-
ing to ISHLT criteria after the examination
of three or four fragments of each endomyo-
cardial biopsy. One fragment of the biopsy
was snap-frozen and stored in liquid nitro-
gen until the time for mRNA extraction. The
study comprised 19 biopsies with rejection
(ISHLT grade ³1B, with two biopsies being
grade 1B, one grade 2, 15 grade 3A, and one
grade 3B), six without histological signs
(grade 0 biopsies) of rejection and collected
7 to 15 days prior to the histological diagno-
sis of rejection (pre-rejection endomyocar-
dial biopsies), and 14 without histological
signs of rejection and collected more than 15
days before or after the day when the diagno-
sis of rejection was established (endomyo-
cardial biopsies without rejection).
Experiments to optimize the amplification
conditions for each set of primers were per-
formed with mRNA extracted from phytohe-
magglutinin-stimulated (Difco, Detroit, MI,
USA) peripheral blood mononuclear cells from
a normal donor, as previously described (17).
After a 48-h incubation period, the cells from
10 wells were pooled, pelleted, and resus-
pended in 0.4 ml of extraction buffer
(QuickPrep Micro mRNA Purification Kit,
Pharmacia Biotech, Uppsala, Sweden). The
other steps of mRNA extraction were per-
formed according to manufacturer instructions.
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The biopsy fragment was placed in 0.4
ml extraction buffer and homogenized with
a Handishear AC homogenizer (VirTis Com-
pany, Gardiner, NY, USA) and the extracted
mRNA was resuspended in 60 µl of diethyl-
polycarbonate-treated water (0.1 g%).
Reverse transcription was performed on
19 µl of the isolated mRNA with 2 µl of
Moloney murine leukemia virus reverse tran-
scriptase (200 U/µl; Gibco-BRL, Gaithers-
burg, MD, USA), 2 µl of oligo(dT)12-18 primer
at 100 µg/ml (Pharmacia Biotech), and 10 µl
of 10 mM dNTPs (Pharmacia Biotech). The
remaining components of the mixture were
10 µl of reverse transcription buffer, 5 µl of
0.1 M dithiothreitol solution, 1 µl of bovine
serum albumin at 1 mg/ml (all from Gibco
BRL), and 2 µl (20 U) of placental ribonu-
clease inhibitor (Pharmacia Biotech). This
mixture was first incubated at 37oC for 60
min, and then at 65oC for 10 min.
Primers used in PCR were synthesized by
Gibco BRL and the sense (S) and antisense
(AS) sequences of the oligonucleotides were
as follows: ß-actin - S: 5 CGTGACATTAA
GGAGAAGCTG 3, AS: 5 CTCAGGAGG
AGCAATGATCTTGA 3 (product size 375
bp); CD40L - S: 5 CGGAACTGTGGGTAT
TT 3, AS: 5 ACTTTTTGCTGTGTATC 3
(product size 520 bp); IFN-g - S: 5 CCAGAG
CATCCAAAAGAGTGTG 3, AS: 5 CTAG
TTGGCCCCTGAGATAAAG 3 (product
size 510 bp); FasL - S: 5 GCCTGTGTCTCC
TTGTGA 3, AS: 5 GCCACCCTTCTTAT
ACTT 3 (product size 321 bp).
Sterile injection-grade water was used
instead of cDNA as a negative control. The
reaction mixture for PCR amplification con-
sisted of 5 µl of cDNA, 10 mM of each
dNTP, 250 ng of each primer, 5 µl of 10X
concentrated PCR buffer, 2.5 mM MgCl2,
and 2.5 U of Taq polymerase (Cenbiot, Porto
Alegre, RS, Brazil) in a total volume of 50
µl. Samples were denatured at 94oC for 60 s,
annealed at 55oC for 45 s, and extended at
72oC for 45 s. This cycle was carried out 40
times in a thermocycler (GeneAmp PCR
System 9600, Perkin Elmer Cetus, Norwalk,
CT, USA). All samples were initially tested
with the ß-actin primers, as a control for
successful RNA extraction and cDNA am-
plification. Thereafter, the samples were
tested in duplicate with the primers for each
marker, in parallel with primers for ß-actin.
Table 1. CD40L, IFN-g, and FasL mRNA levels (target mRNA/ß-actin mRNA) in endomyocardial biopsies.
Biopsies Number Median mRNA Percentage of positive
levels biopsies (mRNA
 expression >zero)*
CD40L IFN-g FasL CD40L IFN-g FasL
Without histological evidence of rejection 14 0 0 0 28.6 21.4 42.8
(grade 0) and collected at least 15 days (4/14) (3/14) (6/14)
before or after rejection
Pre-rejection, i.e., without histological 6 0.036 0.086 0.042 66.6 83.3 66.6
evidence of rejection (grade 0) and (4/6) (5/6) (4/6)
collected 7 to 15 days before rejection
With rejection (at least ISHLT grade ³1B) 16-19 0.116 0.080 0.156 93.7 84.2 94.4
(15/16) (16/19) (17/18)
*Fisher’s exact test: a) with rejection x without rejection: CD40L, P<0.003; IFN-g, P<0.0009; FasL, P<0.002; b)
pre-rejection x without rejection: CD40L, not significant; IFN-g, P = 0.006; FasL, not significant; c) pre-rejection
x rejection: CD40L, P<0.06; IFN-g, not significant; FasL, P<0.02. CD40L, CD40 ligand; IFN-g, interferon-g;
FasL, Fas ligand.
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A 14-µl aliquot of the PCR product was
analyzed by electrophoresis on ethidium bro-
mide-stained 2% agarose gels (w/v). Prod-
ucts were identified by comparison with a
molecular weight marker (f-174-RF DNA/
HincII Digest, Pharmacia Biotech). The im-
age of the gel was captured with a Kodak
DC120 zoom digital camera and the band
intensity was measured using the Kodak Digi-
tal Science - Electrophoresis Documenta-
tion and Analysis System 120 software. The
levels of expression of the markers were
normalized by the ß-actin expression level in
each sample (intensity of the band of the
marker/intensity of the ß-actin band).
The median mRNA levels in the three
groups of biopsies, as well as the percentage
of biopsies positive for the markers, are pre-
sented in Table 1, and the individual values
are shown in Figure 1A. As the majority of
the no rejection biopsies did not present
detectable mRNA levels of the markers, the
quantitative data were transformed into quali-
tative data and the groups were compared by
the Fisher exact test. A biopsy was consid-
ered to be positive for a given marker when
its mRNA level was above the median value
of the group without rejection, i.e., above the
zero level. The number of positive biopsies
was significantly higher in the rejection than
in the no rejection group in respect to all the
markers (CD40L, P<0.003; IFN-g, P<0.0009;
FasL, P<0.002), while the number of posi-
tive biopsies in the pre-rejection group was
Figure 1. Expression of CD40L, IFN-g and FasL genes in
endomyocardial biopsies. A, CD40L, FasL and IFN-g
mRNA levels (target mRNA/ß-actin mRNA) in the
samples without rejection collected more than 15 days
before or after rejection (No-R), in the samples without
rejection collected 7 to 15 days before rejection (Pre-
R), and in the samples with rejection (R). The horizontal
lines represent the median values. B, Kinetics of
intragraft IFN-g mRNA levels in six patients for whom
no rejection, pre-rejection, and rejection biopsy samples
were available. Each line represents one patient.
CD40L, CD40 ligand; IFN-g, interferon-g; FasL, Fas
ligand.
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higher than in the no rejection group only
regarding IFN-g mRNA expression (P<0.02).
Figure 1B illustrates the kinetics of intragraft
IFN-g mRNA expression in six patients for
whom pre-rejection biopsies and the corre-
sponding no rejection (in 4 cases) and rejec-
tion samples were available.
Among the six pre-rejection biopsies ex-
amined, only one failed to show an incre-
ment of IFN-g mRNA. It is interesting to
note that while the five cases that presented
increased IFN-g mRNA prior to rejection
corresponded to typical reversible cellular
acute rejection episodes, the one that did not
present this increase was a case of irrevers-
ible rejection with histological features of
vascular acute rejection. Furthermore, this
recipient developed anti-HLA antibody dur-
ing this rejection episode, representing the
only one who did so among 12 cardiac al-
lograft recipients (including all the recipi-
ents of the present study) previously investi-
gated regarding post-transplant antilympho-
cytic antibody production (20).
The results of the present study confirm
previous data reported by our group and
others concerning increased intragraft ex-
pression of IFN-g, CD40L and FasL genes
(9,11,14,17,18) during acute cardiac or kid-
ney allograft rejection. More importantly,
the present results also confirm our previous
observation regarding the predictive value
of increased IFN-g gene expression for the
occurrence of acute cellular rejection (17,18).
Given the importance of the recognition of
rejection to ensure proper immunosuppres-
sive therapy, we propose the measurement
of IFN-g mRNA levels in endomyocardial
biopsies, especially during the critical initial
six-month period when the incidence of re-
jection is at its peak. These levels could be
used as a guide for early anti-rejection treat-
ment or at least to indicate another biopsy
within a shorter interval than that routinely
scheduled. Considering the relatively small
number of patients evaluated in the present
study, further investigations are needed to de-
fine the sensitivity and specificity of this test.
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